Pozen and Xcel MT 300 “not approvable”
Executive Summary
Pozen and Xcel receive "not approvable" letter from FDA for their migraine treatment MT 300. FDA concluded the drug failed to achieve statistical significance versus placebo for relief at two hours of secondary symptoms of migraine (nausea, sensitivity to light and sensitivity to sound)...